Eleos Health and Kipu Health Announce Partnership to Deliver AI-Powered Insights to Behavioral Health Providers
Kipu Health, the leading technology partner for mental health and addiction service providers, and Eleos Health, the leader in AI for behavioral health, today announced a partnership aimed at delivering meaningful insights and efficiencies to behavioral health providers. By enabling Eleos Health’s…
Agilus Diagnostics launches advanced laboratory in Bongaigaon
Agilus Diagnostics, a subsidiary of Fortis Healthcare Limited., today announced the launch of a new laboratory in Bongaigaon, Assam. The advanced laboratory has the capacity to process 25,000+ samples in a month ranging from simple routine tests to semi-specialized and…
Bracco Announces Long-Term Strategic Partnership with ulrich medical for Syringeless Magnetic Resonance Injectors
Bracco, a global leader in diagnostic imaging, and ulrich GmbH & Co. KG, a renowned German medical device manufacturer specializing in contrast media injectors and spinal implants, announced today a new long-term partnership that will bring a Bracco-branded, state-of-the-art MR…
Senhwa Biosciences Received US FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that U.S. Food and Drug Administration has approved its Phase II IND application of Silmitasertib(CX-4945) to treat patients…
Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis
Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing first-in-class new therapies for the treatment of blinding ocular diseases, today announced the successful outcome of a Type C meeting with the U.S. Food and Drug Administration…
BioCare In-House Expertise to Guide Customers on Effectively Preparing for the Drug Supply Chain Security Act (DSCSA)
BioCare today released a white paper on the Drug Supply Chain Security Act (DSCSA) and how companies can prepare for compliance with the U.S. Food and Drug Administration’s (FDA) requirements to ensure all medications are genuine, uncontaminated, and uncompromised. The DSCSA…
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of DISCOVER TD™, an interactive digital tool designed to help healthcare providers learn about and identify tardive dyskinesia. Built in collaboration with clinical experts and Level Ex, “the world’s leading medical video game studio,” DISCOVER…
Genetics of Nearby Healthy Tissue May Help Catch Lung Cancer’s Return
Genetic information collected from seemingly healthy tissue near lung tumors may be a better predictor of whether cancer will come back after treatment than analysis of the tumors themselves, according to new research led by NYU Langone Health and its…
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough, and prurigo nodularis, today announced that senior management will host…
Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India
Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited (“Intas”) for the development and commercialisation in Europe and India for several indications including ES-SCLC, and specific formulation of HANSIZHUANG (serplulimab injection), Henlius’ novel anti-PD-1 mAb. In June 2018,…
